Related references
Note: Only part of the references are listed.Apalutamide and Overall Survival in Prostate Cancer
Matthew R. Smith et al.
EUROPEAN UROLOGY (2021)
Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis
Laila A Gharzai et al.
LANCET ONCOLOGY (2021)
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
Michael S. Hofman et al.
LANCET (2020)
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Cora N. Sternberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation
Wanling Xie et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer
Colette A. Whitney et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2019)
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
User's guide to correlation coefficients
Haldun Akoglu
TURKISH JOURNAL OF EMERGENCY MEDICINE (2018)
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer
Wanling Xie et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH
Daniel M. Moreira et al.
CLINICAL GENITOURINARY CANCER (2017)
Testing independence of bivariate interval-censored data using modified Kendall's tau statistic
Yuneung Kim et al.
BIOMETRICAL JOURNAL (2015)
Adjuvant Leuprolide With or Without Docetaxel in Patients With High-Risk Prostate Cancer After Radical Prostatectomy (TAX-3501)
Michael T. Schweizer et al.
CANCER (2013)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Death in patients with recurrent prostate cancer after radical prostatectomy: Prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality
Stephen J. Freedland et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy
SJ Freedland et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Share Paper
